What are the precautions for Naxitamab injection?

In clinical studies of Naxitamab Injection (Naxitamab) , warnings and precautions such as serious infusion-related reactions, neurotoxicity, hypertension, embryo-fetal toxicity, etc. have occurred. If they occur, Naxitamab Injection must be permanently discontinued according to the severity. Naxitamab Injection.

1. Neurotoxicity: Nasitumumab injection can cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis and reversible posterior leukoencephalopathy syndrome.

(1) Pain: Pain that occurred in clinical studies included abdominal pain, bone pain, neck pain, and limb pain, with a median duration of less than one day; drugs for the treatment of neuropathic pain (such as gabapentin) and oral opioids were used in advance. Intravenous opioids were administered as needed for breakthrough pain.

(2) Transverse myelitis: Patients who develop transverse myelitis should permanently discontinue use of nacituzumab injection.

(3) Reversible posterior leukoencephalopathy syndrome (RPLS): In the clinical study, the event occurred on the days 2 and 7 after the completion of the first cycle of Nasiltuzumab Injection. Monitor blood pressure during and after infusion of narcistumumab injection and evaluate for neurological symptoms in the event of symptomatic RPLS.

(4) Peripheral neuropathy: including peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia and neuralgia. Most signs and symptoms of neuropathy begin on the day of the injection.

(5) Nervous disorders of the eyes: including anisocoria, blurred vision, accommodation disorders, mydriasis, visual impairment and photophobia. The median duration of ocular neurological impairment in clinical studies was 17 days.

(6) Long-term urinary retention: 4% of patients in one study experienced urinary retention, and 4% of patients in another study experienced urinary retention. All events in both studies occurred on the day of infusion of nascituzumab injection and lasted from days 0 to 24. In patients with urinary retention that does not resolve after discontinuation of opioids, nacertuzumab injection should be permanently discontinued.

2. Severe infusion-related reactions: including fluid resuscitation, administration of bronchodilators and corticosteroids, intensive care unit, reduction in infusion rate or interruption of nasitomab injection infusion. Infusion-related reactions include hypotension, bronchospasm, hypoxia, and stridor. Premedicate with antihistamines, acetaminophen, H2 antagonists, and corticosteroids as recommended. In an environment where cardiopulmonary resuscitation drugs and equipment are available, monitor patients closely for signs and symptoms of infusion reactions during each infusion of Nacertuzumab Injection and for at least 2 hours after completion of the infusion.

3. Hypertension: In both studies, most events occurred on the day of Danyelza injection and within 9 days of Danyelza injection. Do not use nacertuzumab injection in patients with uncontrolled hypertension. Monitor blood pressure during the infusion and at least once daily on Days 1 through 8 of each Nasiltuzumab Injection cycle and assess for hypertensive complications, including RPLS. InterruptNasitumumab Injection infusion and resume at a lower rate.

4. Embryo-Fetal Toxicity: According to its mechanism of action, pregnant women taking noxituzumab injection may cause harm to the fetus. Advise females of reproductive potential to use effective contraception during treatment with nocetuzumab injection and for two months after the last dose.

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.